Biocept, Inc. (BIOCQ)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Biocept, Inc. (BIOCQ) with AI Score 44/100 (Weak). Biocept, Inc. is a molecular oncology diagnostics company that develops and commercializes clinical diagnostic laboratory assays. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 17, 2026Biocept, Inc. (BIOCQ) Healthcare & Pipeline Overview
Biocept, Inc. focuses on developing and commercializing molecular oncology diagnostics, including assays for identifying rare tumor cells and cell-free tumor DNA. The company's assays target various cancers, providing information for targeted therapy. Biocept filed for Chapter 7 bankruptcy in 2023 and is undergoing liquidation, impacting its market position.
Investment Thesis
Biocept, Inc. filed for Chapter 7 bankruptcy on October 13, 2023, and is currently undergoing liquidation. The company's negative profit margin of -124.1% and gross margin of -10.0% reflect significant financial challenges. The company's beta of 3.98 indicates high volatility. Investors should note the company's bankruptcy status and the implications for potential recovery or asset distribution. Given the liquidation process, traditional investment metrics may not be applicable. The company's future prospects are uncertain, contingent on the bankruptcy proceedings and any potential asset sales or restructuring.
Based on FMP financials and quantitative analysis
Key Highlights
- Market Cap: $0.00B, reflecting the company's distressed financial state and ongoing liquidation.
- P/E Ratio: -0.01, indicating negative earnings and the company's lack of profitability.
- Profit Margin: -124.1%, highlighting significant losses and financial instability.
- Gross Margin: -10.0%, demonstrating that the company's cost of goods sold exceeded its revenue.
- Beta: 3.98, indicating high volatility compared to the market, likely exacerbated by the bankruptcy proceedings.
Competitors & Peers
Strengths
- Proprietary clinical diagnostic laboratory assays
- Focus on molecular oncology diagnostics
- Testing services for various solid tumor indications
Weaknesses
- Chapter 7 bankruptcy filing
- Negative profit and gross margins
- Limited financial resources
Catalysts
- Ongoing: Bankruptcy proceedings may lead to asset sales or licensing agreements.
- Ongoing: Potential for restructuring of debt and operations (unlikely).
Risks
- Ongoing: Liquidation process may result in complete loss of investment.
- Potential: Competition from larger diagnostic companies.
- Potential: Technological obsolescence.
- Potential: Limited financial resources hinder future development.
Growth Opportunities
- Expansion of Liquid Biopsy Applications: Liquid biopsies are gaining traction in cancer diagnostics due to their non-invasive nature and ability to provide real-time monitoring of disease progression. Biocept could have explored expanding its liquid biopsy assays to cover a broader range of cancer types and stages, potentially tapping into a market projected to reach $7.1 billion by 2028. However, the bankruptcy filing prevents further development.
- Strategic Partnerships with Pharmaceutical Companies: Collaborating with pharmaceutical companies to develop companion diagnostics for targeted therapies could have provided a significant revenue stream. By offering assays that identify patients most likely to respond to specific drugs, Biocept could have positioned itself as a valuable partner in drug development. The global companion diagnostics market is expected to reach $8.7 billion by 2027.
- Geographic Expansion into International Markets: Expanding its services to international markets, particularly in Europe and Asia, could have diversified Biocept's revenue base and reduced its reliance on the US market. The increasing prevalence of cancer globally and the growing adoption of personalized medicine are driving demand for molecular diagnostics in these regions. However, the bankruptcy filing halts any international expansion plans.
- Development of New Diagnostic Assays: Investing in the development of new diagnostic assays for emerging biomarkers and cancer subtypes could have enhanced Biocept's competitive advantage. By staying at the forefront of scientific advancements, the company could have attracted new customers and expanded its market share. The market for new diagnostic assays is constantly evolving, driven by ongoing research and technological breakthroughs.
- Integration of Artificial Intelligence and Machine Learning: Incorporating AI and machine learning technologies into its diagnostic platforms could have improved the accuracy and efficiency of Biocept's assays. AI can be used to analyze complex genomic data and identify patterns that may be missed by human analysis, leading to more precise diagnoses and treatment decisions. The AI in healthcare market is projected to reach $45 billion by 2026.
Opportunities
- Potential for asset sales or licensing agreements
- Restructuring of debt and operations (unlikely)
- Future advancements in molecular diagnostics
Threats
- Ongoing liquidation process
- Competition from larger diagnostic companies
- Technological obsolescence
Competitive Advantages
- Proprietary clinical diagnostic laboratory assays.
- Focus on identifying rare tumor cells and cell-free tumor DNA.
- Testing services for a range of solid tumor indications.
About BIOCQ
Biocept, Inc. was founded in 1997 and is headquartered in San Diego, California. The company specialized in developing and commercializing proprietary clinical diagnostic laboratory assays designed to identify rare tumor cells and cell-free tumor DNA from blood and cerebrospinal fluid (CSF). These assays provided healthcare providers with information to identify oncogenic alterations, enabling targeted therapy for cancer patients at diagnosis, progression, and during monitoring to identify resistance mechanisms. Biocept offered assays for solid tumor indications, including breast cancer, non-small cell lung cancer (NSCLC), gastric cancer, colorectal cancer, prostate cancer, pancreaticobiliary cancer, and ovarian cancer. The company also provided cerebrospinal fluid tumor cell and ctDNA and ctRNA testing services to various medical professionals, including oncologists, neuro-oncologists, and pathologists. Biocept also offered clinical trial and research services to pharmaceutical and biopharmaceutical companies. The company had collaborations with CLEARED4 to develop a system for tracking COVID-19 testing and with Protean BioDiagnostics, Inc. to research EGFR status in NSCLC patients. However, on October 13, 2023, Biocept, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware.
What They Do
- Develops clinical diagnostic laboratory assays.
- Commercializes assays for identifying rare tumor cells.
- Identifies cell-free tumor DNA from blood and CSF.
- Offers assays for solid tumor indications like breast and lung cancer.
- Provides cerebrospinal fluid tumor cell testing services.
- Offers clinical trial and research services to pharmaceutical companies.
Business Model
- Develops and commercializes proprietary diagnostic assays.
- Generates revenue through sales of diagnostic testing services.
- Partners with pharmaceutical companies for clinical trials and research services.
Industry Context
Biocept operated in the molecular diagnostics market, which is characterized by rapid innovation and increasing demand for personalized medicine. The industry is driven by advancements in genomics and proteomics, leading to the development of more precise and effective diagnostic tools. Key competitors include BSPM, CRFTF, CWWBF, HTGMQ, and MDVLQ. However, Biocept's bankruptcy and liquidation significantly impact its competitive positioning within this landscape. The industry continues to grow, but Biocept's ability to participate is severely limited.
Key Customers
- Medical oncologists
- Neuro-oncologists
- Pathologists
- Pharmaceutical companies
- Biopharmaceutical companies
Financials
Chart & Info
Biocept, Inc. (BIOCQ) stock price: Price data unavailable
Latest News
No recent news available for BIOCQ.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for BIOCQ.
Price Targets
Wall Street price target analysis for BIOCQ.
MoonshotScore
What does this score mean?
The MoonshotScore rates BIOCQ's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Leadership: Soon Kap Hahn
Chief Executive Officer
Soon Kap Hahn served as the Chief Executive Officer of Biocept, Inc. His background includes experience in managing teams and overseeing the operations of a molecular oncology diagnostics company. He was responsible for leading the company's strategic direction and overseeing the development and commercialization of its diagnostic assays. His leadership involved navigating the complexities of the healthcare industry and the challenges of a competitive market.
Track Record: Under Soon Kap Hahn's leadership, Biocept focused on developing and commercializing clinical diagnostic laboratory assays. However, the company ultimately filed for Chapter 7 bankruptcy in October 2023, indicating significant financial and operational challenges during his tenure. The company's liquidation reflects the difficulties in achieving sustainable profitability and market success.
BIOCQ OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Biocept, Inc. did not meet the requirements for the higher tiers (OTCQX and OTCQB). Companies in this tier may be distressed, undergoing bankruptcy, or have chosen not to comply with the disclosure requirements of the higher tiers. Trading on the OTC Other market carries significant risks due to the lack of regulatory oversight and limited financial disclosure compared to NYSE or NASDAQ-listed companies. Investors should exercise extreme caution when considering investments in this tier.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure
- Low liquidity and wide bid-ask spreads
- Bankruptcy and liquidation proceedings
- Potential for delisting and loss of investment
- Lack of regulatory oversight
- Verify the company's bankruptcy status and court filings.
- Assess the potential for asset recovery or distribution.
- Review any available financial statements or disclosures.
- Understand the risks associated with OTC Other trading.
- Evaluate the company's management and governance structure.
- Consult with a financial advisor before investing.
- Consider the potential for complete loss of investment.
- Prior history as a publicly traded company
- Established operations in the molecular diagnostics industry
- Previous collaborations with pharmaceutical companies
BIOCQ Healthcare Stock FAQ
What does Biocept, Inc. do?
Biocept, Inc. was a molecular oncology diagnostics company that developed and commercialized clinical diagnostic laboratory assays. These assays were designed to identify rare tumor cells and cell-free tumor DNA from blood and cerebrospinal fluid. The company's assays provided information to healthcare providers to identify oncogenic alterations, enabling targeted therapy for cancer patients. However, Biocept filed for Chapter 7 bankruptcy in October 2023 and is currently undergoing liquidation.
What do analysts say about BIOCQ stock?
Given Biocept's Chapter 7 bankruptcy filing and its current status on the OTC Other market, traditional analyst coverage is likely limited or non-existent. The company's distressed financial state and ongoing liquidation process make it difficult to apply standard valuation metrics. Investors should focus on the bankruptcy proceedings and potential asset recovery rather than traditional stock analysis.
What are the main risks for BIOCQ?
The primary risk for BIOCQ is the ongoing liquidation process under Chapter 7 bankruptcy. This process may result in a complete loss of investment for shareholders. Additional risks include limited financial disclosure, low liquidity on the OTC Other market, and the potential for delisting. Investors should carefully consider these risks before investing in BIOCQ.
What are the key factors to evaluate for BIOCQ?
Biocept, Inc. (BIOCQ) currently holds an AI score of 44/100, indicating low score. Key strength: Proprietary clinical diagnostic laboratory assays. Primary risk to monitor: Ongoing: Liquidation process may result in complete loss of investment.. This is not financial advice.
How frequently does BIOCQ data refresh on this page?
BIOCQ prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven BIOCQ's recent stock price performance?
Recent price movement in Biocept, Inc. (BIOCQ) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary clinical diagnostic laboratory assays. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider BIOCQ overvalued or undervalued right now?
Determining whether Biocept, Inc. (BIOCQ) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying BIOCQ?
Before investing in Biocept, Inc. (BIOCQ), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change due to the bankruptcy proceedings.
- The company's financial condition is highly unstable due to the bankruptcy filing.